38169-74-3

Upstream product

• 129170-94-1 3-((R)-1-Octadecyloxymethyl-2-trityloxy-ethoxy)-isoxazole 
• 83526-53-8 (R)-1,2-Epoxy-3-(octadecyloxy)propan 
• 10585-86-1 1,2-Di-O-isopropyliden-3-O-octadecyl-sn-glycerin 
• 86334-56-7 1-octadecyloxy-3-trityloxy-propan-2-ol 
• 83526-60-7 2-O-Acetyl-1-O-benzyl-3-O-octadecyl-sn-glycerin 
• 83526-52-7 3-O-Octadecyl-2-O-p-toluolsulfonyl-sn-glycerin 
• 83526-54-9 3-O-Octadecyl-1-O-p-toluolsulfonyl-sn-glycerin 
• 83537-01-3 (-)-1-O-octadecyl-2-O-acetyl-sn-glycerol 
• 83526-56-1 (S)-1,2-Epoxy-3-(octadecyloxy)propan 
• 83526-51-6 3-O-Octadecyl-2-O-p-toluolsulfonyl-3-O-trityl-sn-glycerin 
• 83526-50-5 3-O-Octadecyl-1,2-di-O-p-toluolsulfonyl-sn-glycerin 
• 80707-96-6 Ro 15-4454 
• 83526-57-2 (S)-1-(benzyloxy)-3-(octadecyloxy)propan-2-ol 
• 83167-57-1 3-O-Benzyl-1-O-octadecyl-sn-glycerol 

Downstream Products

• 80459-30-9 2-O-Benzyl-1-O-octadecyl-3-O-trityl-sn-glycerin 
• 129170-95-2 3-((S)-1-Octadecyloxymethyl-2-trityloxy-ethoxy)-isoxazole 
• 1226872-62-3 (R)-1-octadecyl-2-(5'-hexenyl)-3-trityl-glycerol 
• 80483-86-9 2-O-Benzyl-1-O-octadecyl-sn-glycero-3-phosphorylcholin 
• 74430-89-0 Lyso-platelet-activating factor (C₁₈) 
• 105415-93-8 (R)-2-benzyloxy-3-octadecyloxypropyl 2-(N-methylpyrrolidinio)ethyl phosphate 
• 105435-57-2 (R)-2-benzyloxy-3-octadecyloxypropyl 2-(diethylmethylammonio)ethyl phosphate 
• 65492-82-2 (+)-Edelfosine 
• 80707-93-3 (S)-1-O-octadecyl-2-O-benzyl-glycerol 
• 83167-59-3 1-O-octadecyl-2-O-methyl-sn-glycerol 
• 150283-40-2 1-O-octadecyl-2-O-methyl-3-O-trityl-sn-glycerol 
• 150283-41-3 1-O-octadecyl-2-O-ethyl-3-O-trityl-sn-glycerol 

Relevant academic research and scientific papers

Synthesis of glyceryl ethers in high optical purity via ruthenium catalyzed asymmetric hydrogenation

1-O-octadecyl-3-O-trityl-glycerol and 1-O-benzyl-3-O-trityl-glycerol can be prepared by asymmetric catalytic hydrogenation in O.P.> 96% and 87-88% respectively.

An efficient synthesis of Platelet-Activating Factor (PAF) via 1-o-alkyl-2-o-(3-isoxazolyl)-SN-glycero-3-phosphocholine, a new PAF agonist utilization of the 3-isoxazolyloxy group as a protected hydroxyl

Potent PAF agonists (R)-3a,b were synthesized and converted into PAF. Key steps include Mitsunobu reaction of a chiral secondary alcohol with 3-hydroxyisoxazole as the acidic component, and hydrogenolytic ring cleavage of the resulting 3-isoxazolyloxy gro